You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

405 Results
Guidelines and Advice
Status: In-Review
ID: GL END 3-23
Version: N/A
Oct 2021
Document
Mar 2022
Document
Mar 2022
Document
Mar 2022
Regimen
Cancer Type:
Breast
Show More Show more tags
, Show Less Show fewer tags
Intent: Neoadjuvant
Funding:
New Drug Funding Program
    Pembrolizumab - Previously Untreated High-Risk Early-Stage Triple Negative Breast Cancer
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
pembrolizumab,
DOXOrubicin,
cyclophosphamide
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Sep 2023
Regimen
Cancer Type:
Hematologic, 
Leukemia - Chronic Myeloid (CML)
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Funding:
Exceptional Access Program
    asciminib - For the treatment of Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase, based on criteria
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
asciminib
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Jul 2025
Document
Apr 2022
Document
Apr 2022
Document
Apr 2022
Document
Apr 2022
Drug
Other Name(s): Onureg®
Quick Link(s): Drug Monograph, Patient Info Sheet
Aug 2023

Pages